Showing results (81-90 of 672) with videos related to
Sort By:
Pageof 68
Best Practice & Research. Clinical Endocrinology & Metabolism|December 7, 2007
PPAR agonists: multimodal drugs for the treatment of type-2 diabetesBarbara Gross, Bart StaelsDiabetes & Vascular Disease Research|June 10, 2008
The nuclear receptors Rev-erbs and RORs integrate circadian rhythms and metabolismHélène Duez, Bart StaelsCurrent Obesity Reports|February 12, 2025
Circadian Disruption and the Risk of Developing ObesityHélène Duez, Bart StaelsDrugs|June 30, 2007
Bile acid sequestrants and the treatment of type 2 diabetes mellitusBart Staels, Folkert KuipersThe Journal of Biological Chemistry|November 30, 2013
Peroxisome proliferator-activated receptor γ regulates genes involved in insulin/insulin-like growth factor signaling and lipid metabolism during adipogenesis through functionally distinct enhancer classesFrédérik Oger, Julie Dubois-Chevalier, Céline Gheeraert, et al.Expert Opinion on Investigational Drugs|August 29, 2014
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetesBertrand Cariou, Bart StaelsCurrent Opinion in Lipidology|March 14, 2007
The orphan nuclear receptor Rev-erbalpha: a transcriptional link between circadian rhythmicity and cardiometabolic diseaseCoralie Fontaine, Bart StaelsTrends in Pharmacological Sciences|April 7, 2007
FXR: a promising target for the metabolic syndrome?Bertrand Cariou, Bart StaelsNuclear Receptor Signaling|April 11, 2006
Potential roles of ROR-alpha in cardiovascular endocrinologySaara Laitinen, Bart StaelsTrends in Cardiovascular Medicine|April 26, 2008
Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanismsRéjane Paumelle, Bart StaelsPageof 68